Martin Shkreli has just under a year to prep for his trial on federal securities charges.
Judge Kiyo Matsumoto set the trial date for June 26 next year, according to wire reports.
Shkreli became infamous last year after his startup Turing grabbed an old drug called Daraprim and immediately jacked up the price by 5,000%-plus. But while the scandal and resulting outcry may have made him a tempting target for federal investigators—especially as the youthful looking exec took to Twitter to taunt and sneer at his legion of tormentors—it has nothing to do with his federal case.
The charges center around his time as CEO of Retrophin and running his defunct hedge funds. Federal investigators accused him of looting Retrophin, using it as his own personal piggy bank, as well as repeatedly lying to investors about the hedge fund operations. A few weeks ago, the feds added a charge of conspiracy to commit securities fraud.
Shkreli these days likes to reserve his most scorching opinions for the journalists covering his case. He had this for a CNBC promo on his case.
The road the the Pulitzer is paved with Pokemon scoops. https://t.co/uRSpNWzaJz
— Martin Shkreli (@MartinShkreli) July 14, 2016
Get Endpoints News in your inbox
Newsletters for those who discover, develop, and market drugs. Enjoy the news with the story intact — entire articles in your inbox, no clicks required. Join 12,000+ biopharma pros who read Endpoints News every day. Free subscription.
Subscribe to Endpoints
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.